How to Get Praluent (Alirocumab) in Maryland

What Is Praluent and Why Maryland Patients Seek It

Praluent is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By inhibiting PCSK9, alirocumab preserves more LDL receptors, allowing the liver to clear more LDL cholesterol from the bloodstream. The FDA approved alirocumab in July 2015 for adults with HeFH or clinical ASCVD who need additional LDL-C lowering on top of maximally tolerated statin therapy [1].

Maryland has a higher-than-average burden of cardiovascular disease. The CDC reports that heart disease accounts for roughly 23% of all deaths in Maryland annually [2]. Patients who have already had a heart attack, undergone coronary revascularization, or carry a confirmed familial hypercholesterolemia diagnosis frequently cannot reach their LDL-C targets with statins and ezetimibe alone. That is the patient population for which alirocumab was designed.

The ODYSSEY OUTCOMES trial (N=18,924) published in the New England Journal of Medicine in 2018 randomized patients with recent acute coronary syndrome to alirocumab 75 to 150 mg every 2 weeks versus placebo, both on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced major adverse cardiovascular events by 15% (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001) and produced a mean LDL-C reduction of 54.7% from baseline [3]. In the pre-specified subgroup of patients with baseline LDL-C of 100 mg/dL or higher, the absolute risk reduction was 3.4 percentage points over 3 years.

Those numbers explain why cardiologists across Baltimore, Bethesda, Annapolis, and Frederick are prescribing it more frequently, and why patients are now searching for faster access through telehealth.

Who Can Prescribe Praluent in Maryland

Any licensed Maryland prescriber with DEA and state prescribing authority may write a Praluent prescription. That includes MDs, DOs, nurse practitioners (NPs) with full practice authority under Maryland law, and physician assistants (PAs) with a supervising physician agreement.

Maryland granted NPs full independent practice authority in 2015 for primary care settings. Since 2021, Maryland NPs working outside primary care settings, including cardiology and lipidology, may also prescribe Schedule II, V controlled substances and all non-controlled medications including PCSK9 inhibitors without mandatory physician oversight, provided they hold the appropriate national certification [4]. PAs in Maryland must maintain a delegation agreement with a supervising physician, but that agreement does not restrict which non-controlled drugs they may prescribe within their scope.

Practically, most Praluent prescriptions in Maryland originate from:

• Cardiologists and interventional cardiologists at health systems such as Johns Hopkins Medicine, University of Maryland Medical System, and MedStar Health
• Lipidologists and endocrinologists managing familial hypercholesterolemia
• Primary care physicians and NPs at telehealth platforms licensed in Maryland

The telehealth option is expanding quickly. Telehealth prescribing of non-controlled medications, including alirocumab, is fully permitted in Maryland after a synchronous audio-video encounter [5]. An asynchronous (store-and-forward) consult alone is generally not sufficient for an initial prescription under Maryland Board of Physicians guidance; a live encounter is required for the first visit.

What Labs You Need Before Starting Praluent in Maryland

A fasting lipid panel is non-negotiable. Most Maryland insurers and the Praluent prior authorization criteria require a documented baseline LDL-C on maximally tolerated statin therapy, typically showing LDL-C above 70 mg/dL for ASCVD patients or above 100 mg/dL for FH patients without prior ASCVD.

The core lab panel before starting alirocumab in Maryland:

Fasting lipid panel. Drawn after at least 9 to 12 hours of fasting. Must reflect LDL-C while on the highest tolerated statin dose (and ideally ezetimibe). Most PA forms require this to have been drawn within the prior 90 days.

Liver function tests (ALT, AST, total bilirubin). Alirocumab is not hepatically metabolized in the same way small-molecule drugs are, but baseline LFTs are standard practice and required by several commercial payers in Maryland.

TSH. Hypothyroidism causes secondary hyperlipidemia. If the diagnosis has not been ruled out or the patient has new-onset hyperlipidemia, a TSH should be on record.

CK (creatine kinase). Not universally required but recommended if the patient reports myalgia on statin therapy, because statin intolerance is often cited as a qualifying reason for PCSK9 inhibitor access.

HbA1c or fasting glucose. Useful for cardiovascular risk stratification and sometimes requested by commercial payers to confirm the ASCVD risk tier.

None of these require a specialist order. A primary care telehealth visit can generate the lab requisition, the patient goes to a Maryland-based LabCorp or Quest location, and the results are uploaded to the prescribing platform before the PA is filed.

How Maryland Prior Authorization for Praluent Works

Prior authorization is the single biggest source of delay. Understand the process before you start.

Maryland Medicaid (HealthChoice managed care organizations) covers alirocumab for HeFH and established ASCVD with a PA requirement. The Maryland Medicaid preferred drug list currently places PCSK9 inhibitors in a non-preferred tier requiring step therapy documentation [6]. That means you must have a documented trial and inadequate response or intolerance to at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and often ezetimibe 10 mg before Medicaid will approve alirocumab.

Commercial insurers in Maryland, including CareFirst BlueCross BlueShield, UnitedHealthcare of the Mid-Atlantic, Aetna, and Cigna, use similar criteria. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitor therapy for ASCVD patients with LDL-C of 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe [7]. Most Maryland commercial PA forms mirror these guideline thresholds directly.

Typical PA documentation checklist for Maryland:

1. Current LDL-C lab result (within 90 days) on statin therapy
2. Statin name, dose, and duration of trial
3. Ezetimibe trial documentation (or contraindication)
4. ICD-10 diagnosis code: E78.01 (FH, pure hypercholesterolemia) or I25.10 (ASCVD) or related codes
5. Prescriber name, NPI, and Maryland license number
6. Clinical notes supporting the indication

Expect 3, 14 business days for commercial PA decisions. Medicaid PA decisions under Maryland regulations must be rendered within 14 calendar days for non-urgent requests and 72 hours for expedited requests. If denied, your prescriber can file a peer-to-peer appeal, which succeeds in approximately 35 to 50% of cases when clinical documentation is complete.

Regeneron and Sanofi also offer the Praluent Copay Card, which caps out-of-pocket costs at $0 per month for commercially insured patients meeting income criteria, and the Praluent Patient Assistance Program for uninsured or underinsured patients. Both programs are accessible at the manufacturer's website and through specialty pharmacies that handle Praluent in Maryland.

How to Get a Praluent Prescription Through Maryland Telehealth

The fastest route to a Praluent prescription for most Maryland patients who are not already under cardiology care is a telehealth visit with a platform licensed in Maryland.

Step 1: Gather your records. Collect your most recent lipid panel, current medication list, any prior statin trial history, and your insurance card. Uploading these before the visit saves significant time.

Step 2: Schedule a synchronous audio-video visit. Maryland requires a real-time encounter for the initial Praluent prescription. Visits are typically 20 to 30 minutes.

Step 3: The provider evaluates your candidacy. They will confirm your LDL-C targets, review statin tolerance, and determine whether you meet FDA-approved indications or clinical guideline criteria.

Step 4: Labs if needed. If your lipid panel is older than 90 days, the provider sends a lab requisition to a Maryland LabCorp or Quest site near you.

Step 5: PA filing. The prescriber's team (or the telehealth platform's PA coordinators) submits the prior authorization to your insurer. Most platforms have dedicated PA support staff.

Step 6: Specialty pharmacy fulfillment. Once approved, the prescription is routed to a specialty pharmacy. Praluent requires cold-chain shipping (2, 8°C). Standard delivery within Maryland is 2, 5 business days after PA approval.

Step 7: Injection training. The auto-injector is designed for self-administration. The specialty pharmacy provides injection training materials, and most telehealth platforms offer a brief video consult to walk through the technique.

Total timeline from first telehealth visit to first injection averages 2 to 4 weeks when PA is approved on the first submission. Cases requiring an appeal can extend to 6 to 8 weeks.

Praluent Dosing: What to Expect After Your Prescription Is Filled

The FDA-approved dosing schedule has two options [1]:

75 mg subcutaneous injection every 2 weeks. This is the standard starting dose. In ODYSSEY LONG TERM (N=2,341), this dose reduced LDL-C by a mean of 61% from baseline at 24 weeks [8].

300 mg subcutaneous injection once monthly. This dose is therapeutically equivalent to 75 mg every 2 weeks and is preferred by patients who find biweekly injections burdensome. The 300 mg dose is delivered as two 150 mg injections given back to back at the same site visit.

Dose titration. If LDL-C remains above target at 4 to 8 weeks on 75 mg every 2 weeks, the prescriber may increase to 150 mg every 2 weeks. In ODYSSEY OUTCOMES, patients could be titrated to 150 mg; approximately 16% of patients reached that dose.

Injection sites. Abdomen, thigh, or upper arm. Rotate sites. Do not inject into skin that is tender, bruised, red, or indurated.

Storage. Refrigerate at 36, 46°F (2, 8°C). Do not freeze. May be kept at room temperature (up to 77°F/25°C) for up to 30 days, after which it must be discarded if unused.

Monitoring after starting. A repeat fasting lipid panel at 4 to 8 weeks after initiation or dose change confirms response. Most Maryland prescribers and payers require this lab to continue authorizing the prescription on refill.

The American College of Cardiology's 2022 expert consensus decision pathway states: "For very high-risk ASCVD patients not at LDL-C goal on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended" [7]. Alirocumab and evolocumab (Repatha) are the two FDA-approved PCSK9 monoclonal antibodies; the choice between them is often driven by formulary placement and PA approval speed at a given insurer.

503A Pharmacy Access for Alirocumab in Maryland

Some patients and prescribers ask about compounded alirocumab through Maryland's licensed 503A compounding pharmacies. This question requires a careful answer.

Alirocumab is a biologic (a monoclonal antibody), not a small-molecule drug. FDA regulations under 503A of the Federal Food, Drug, and Cosmetic Act permit compounding pharmacies to prepare "essentially a copy" of a commercially available drug only in very limited circumstances, such as when a patient has a documented allergy to an excipient in the commercial product that cannot be accommodated otherwise [9]. Compounding a full biologic monoclonal antibody requires sterile manufacturing infrastructure far beyond what most 503A pharmacies possess.

Maryland's Board of Pharmacy licenses 503A pharmacies and enforces FDA guidance. A licensed 503A pharmacy in Maryland could theoretically prepare a modified formulation addressing an excipient intolerance, but it cannot produce the alirocumab active pharmaceutical ingredient itself. Patients who see online offers for "compounded PCSK9 inhibitors" at dramatically lower prices should be extremely cautious. These products would not have FDA-reviewed safety or efficacy data.

The practical implication: nearly all Maryland patients will access alirocumab through the FDA-approved commercial Praluent product via a specialty pharmacy, covered by insurance after PA, or through Regeneron/Sanofi's patient assistance program.

Transferring an Existing Praluent Prescription to Maryland

If you have an existing Praluent prescription from another state and are relocating to Maryland, the transfer process is straightforward for the pharmacy side but requires one additional step on the prescriber side.

Maryland does not restrict interstate prescription transfers for non-controlled substances. Your current specialty pharmacy can transfer the active prescription to a Maryland-licensed specialty pharmacy, provided the original prescriber is still active and the prescription has remaining refills. Call the specialty pharmacy's transfer line and provide your Maryland address and preferred Maryland delivery location.

The prescriber step: Maryland law requires that the prescribing clinician hold an active license in Maryland (or a state with reciprocal telehealth privileges) to continue authorizing refills after you establish Maryland residency [5]. If your out-of-state prescriber is not licensed in Maryland, you will need to establish care with a Maryland-licensed provider. That provider will review your records, confirm the indication and current LDL-C response, and reauthorize the prescription. A telehealth visit with a Maryland-licensed platform handles this in a single appointment.

Insurance PA also transfers in the sense that a new PA must be filed with your Maryland-based plan. Bring your prior authorization approval letter from your previous insurer, because it contains exactly the documentation your new Maryland insurer will require.

Cost and Financial Assistance in Maryland

Praluent's list price is approximately $5,850 per year without insurance. In practice, insured Maryland patients pay substantially less.

Commercial insurance with PA approval. With the Praluent Copay Assistance Program, commercially insured patients may pay $0 per month. Eligibility is confirmed at time of specialty pharmacy enrollment.

Maryland Medicaid. After PA approval, the patient's cost-sharing under Medicaid is governed by standard HealthChoice copay schedules, typically $1, $3 per prescription for preferred biologics.

Uninsured patients. The Praluent Patient Assistance Program (myALLIANCE, administered by Sanofi) provides free medication to qualifying patients with income below 600% of the federal poverty level. Applications are submitted through the specialty pharmacy or directly through Sanofi's patient support line.

Medicare Part D. Alirocumab is covered under Medicare Part D plans, though formulary tier and copay vary by plan. The 2023 Inflation Reduction Act cap of $2,000 per year on Medicare Part D out-of-pocket costs benefits beneficiaries on Praluent starting in 2025.

The ACC notes that the cost-effectiveness of alirocumab improves substantially when it is targeted to patients at highest absolute cardiovascular risk, specifically those with baseline LDL-C above 100 mg/dL and recent ACS, which is the population studied in ODYSSEY OUTCOMES [3].

Monitoring and Follow-Up After Starting Praluent in Maryland

Starting alirocumab is not a one-visit process. Maryland-based prescribers, whether in-person or via telehealth, should schedule follow-up at predictable intervals.

4 to 8 weeks post-initiation. Fasting lipid panel to confirm LDL-C response. Most patients see their nadir LDL-C within 4 weeks of the first injection. If LDL-C is not at goal (typically <70 mg/dL for ASCVD, <100 mg/dL for FH without ASCVD), the dose should be titrated from 75 mg to 150 mg every 2 weeks.

Annual re-authorization. Commercial PA in Maryland is typically granted for 12 months. Your prescriber's office or telehealth platform's PA team will initiate renewal approximately 30 to 45 days before expiration using an updated lipid panel and clinical note.

Injection site reactions. Approximately 7.2% of patients in the ODYSSEY program experienced injection site reactions (erythema, pruritus, swelling) versus 5.1% placebo [3]. These are generally mild and self-limiting. Report persistent or worsening skin reactions to your prescriber.

Neurocognitive symptoms. Post-marketing reports prompted an FDA label update in 2017 requiring patient counseling about possible cognitive effects with PCSK9 inhibitors. The EBBINGHAUS sub-study of FOURIER (for evolocumab) found no cognitive impairment signal [10]; ODYSSEY OUTCOMES did not identify a statistically significant neurocognitive difference either. Patients who notice memory changes should report them at their next visit.

Your prescriber should receive your lipid panel results and confirm them before the 90-day mark to ensure both clinical response and PA renewal documentation are current.